Drug Profile
Alpha lactalbumin oleic acid - Hamlet Pharma
Alternative Names: Alpha 1H; HAMLET; Human alpha-lactalbumin made lethal to tumoursLatest Information Update: 02 Feb 2024
Price :
$50
*
At a glance
- Originator Hamlet Pharma AB
- Developer Hamlet Pharma AB; Neurochase
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Bladder cancer
- Preclinical Brain cancer
- No development reported Cancer; Colorectal cancer; Glioblastoma; Papilloma; Skin cancer
Most Recent Events
- 29 Jan 2024 Adverse events and efficacy data from a phase I/II trial in Bladder cancer released by Hamlet Pharma
- 30 Nov 2023 Alpha lactalbumin oleic acid receives fast track status for Bladder cancer in USA
- 28 Aug 2023 No recent reports of development identified for preclinical development in Skin-cancer in Sweden